ClinicalTrials.gg
CompletedNCT02720107Updated Feb 8, 2019Results posted

Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)

A Phase 4 interventional study of fingolimod in Relapsing-remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 26 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
133
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
11th of 19
133 · median 142
Started
2016
the only one that year
Phase 4
14 of 19
none open now
Registered
17th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 11th largest by enrollment, is the only one that started in 2016, is one of 14 in phase 4, and was the 17th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The purpose of this single visit extension study is to explore immune status in RRMS patients treated for at least 48 months with fingolimod. Long-term changes in T cell counts will be compared to short-term changes in immune status (baseline to month 6) after treatment start with fingolimod as assessed in the original Biobank study (CFTY720DDE01).

03

Conditions studied

  • Relapsing-remitting Multiple Sclerosis

Keywords

  • fingolimod
  • Biomarker
  • Multiple sclerosis
  • Relapsing-remitting multiple sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written before any assessment was performed.
  2. Randomized in study CFTY720DDE01 and received at least one dose of study drug (fingolimod) and completed the study.
  3. Continuous intake of fingolimod after end of study CFTY720DDE01 with a maximum treatment interruption of 3 months in total before entering this study.
  4. Parallel participation at study CFTY720DDE02 (Pangaea NIS) was allowed.

Exclusion criteria

Exclusion criteriat:

  1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test.
  2. Patients with onset of an acute relapse had to postpone their evaluation until deemed stable from relapse by treating physician, but at least for 1 month since end of relapse.
  3. Patients that received immunomodulating or MS treatments other than fingolimod since completion of study CFTY720DDE01 as for example: Natalizumab,Alemtuzumab, Dimethyl fumarate, Teriflunomide, intravenous Immunoglobulins,Mitoxantrone, Methotrexate, Azathioprine or experimental immunomodulating-immunosuppressive therapies.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    fingolimod

    Patients did not receive any protocol specified treatment during this follow-up study. Patients remained on their current treatment regime (fingolimod), as determined by their regular treating physician (i.e. 0.5 mg fingolimod daily, single-arm).

    Drug: fingolimod

Interventions

06

What researchers measure

Primary outcomes

  1. Change in T Cells Status (Decrease or Increase) at Month 48 (FAS)

    Aim of trial was to was to show reduction of CD4+ and CD8+ naïve T cells (CCR7+CD45RA+), central memory T cells (CCR7+CD45RA-), central memory Th17 cells (CD4+ CCR4+ and CCR6+), and an elevation of 2 types of effector memory T cells TEM (CCR7- CD45RA-) and TEMRA (CCR7- CD45RA+) in peripheral venous blood. Changes from baseline to month 48 in biomarkers were analyzed for all patients in the FAS.

    Time frame: Baseline up to approximately 48 months

Secondary outcomes

  1. Percentage of Participants With Disability Progression as Measured by Expanded Disability Status Scale (EDSS) (FAS)

    EDSS is a scale for assessing neurologic impairment in MS. It is a two-part system including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The definition of disability progression was based on increases in EDSS from baseline and depended on the EDSS baseline value: Disability progression was defined as a 1.5 increase in EDSS from baseline in subjects with a baseline EDSS score between 0.0 and 0.5, as a 1.0 increase in EDSS from baseline in subjects with a baseline EDSS score between 1.0 and 5.0 inclusive and 0.5 increase from baseline in subjects with EDSS score \> 5.0.

    Time frame: Baseline up to approximately 48 months

  2. Change From Baseline in Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at Month 6 and Month 48 (FAS)

    EDSS is a scale for assessing neurologic impairment in MS. It is a two-part system including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The definition of disability progression was based on increases in EDSS from baseline and depended on the EDSS baseline value: Disability progression was defined as a 1.5 increase in EDSS from baseline in subjects with a baseline EDSS score between 0.0 and 0.5, as a 1.0 increase in EDSS from baseline in subjects with a baseline EDSS score between 1.0 and 5.0 inclusive and 0.5 increase from baseline in subjects with EDSS score \> 5.0.

    Time frame: Baseline, month 6 up to approximately 48 months

  3. Change in Immune Status of B Cells, Monocytes and Natural Killer Cells (NK) Cells (FAS)

    Changes in immune status of B cells (CD19+, CD20+, CD69+), monocytes (CD14+) and NK cells (CD56+) were analyzed as a percentage of parent cell population (CD4+, CD8+ or total lymphocytes) by flow cytometry

    Time frame: Baseline up to approximately 48 months

07

Results

Posted Feb 8, 2019

Participant flow

Participant flow — Overall Study
MilestoneFingolimod
Started130
Completed130
Not completed0

Outcome measures

PrimaryChange in T Cells Status (Decrease or Increase) at Month 48 (FAS)

Aim of trial was to was to show reduction of CD4+ and CD8+ naïve T cells (CCR7+CD45RA+), central memory T cells (CCR7+CD45RA-), central memory Th17 cells (CD4+ CCR4+ and CCR6+), and an elevation of 2 types of effector memory T cells TEM (CCR7- CD45RA-) and TEMRA (CCR7- CD45RA+) in peripheral venous blood. Changes from baseline to month 48 in biomarkers were analyzed for all patients in the FAS.

Time frame:
Baseline up to approximately 48 months
Reported as:
Least squares mean · percentage of parent population
Change in T Cells Status (Decrease or Increase) at Month 48 (FAS)
percentage of parent populationFingolimod
CD4+ Naïve T cells-23.7 ± 0.62
CD4+Central memory T cells-1.2 ± 0.59
CD4+ Effector memory T cells22.2 ± 2.37
CD8+ Naïve T cells-37.2 ± 0.38
CD8+ Central memory T cells-1.6 ± 0.07
CD8+ Effector memory T cells-12.9 ± 1.59
TH17 central memory cells-0.6 ± 0.03
Statistical analysis
  • Fingolimod · ANCOVA · p = < 0.0001 (The ANCOVA model included the covariates center, baseline of corresponding cell counts from Core study, sex and duration of disease until start of Core study)
  • Fingolimod · ANCOVA · p = 0.0493 (The ANCOVA model included the covariates center, baseline of corresponding cell counts from study Core study, sex and duration of disease until start of Core study)
  • Fingolimod · ANCOVA · p = < 0.0001 (The ANCOVA model included the covariates center, baseline of corresponding cell counts from Core study, sex and duration of disease until start of Core study)
  • Fingolimod · ANCOVA · p = < 0.0001 (The ANCOVA model included the covariates center, baseline of corresponding cell counts from Core study, sex and duration of disease until start of Core study)
  • Fingolimod · ANCOVA · p = < 0.0001 (The ANCOVA model included the covariates center, baseline of corresponding cell counts from Core study, sex and duration of disease until start of Core study)
  • Fingolimod · ANCOVA · p = < 0.0001 (The ANCOVA model included the covariates center, baseline of corresponding cell counts from Core study, sex and duration of disease until start of Core study)
  • Fingolimod · ANCOVA · p = < 0.0001 (The ANCOVA model included the covariates center, baseline of corresponding cell counts from Core study, sex and duration of disease until start of Core study)
SecondaryPercentage of Participants With Disability Progression as Measured by Expanded Disability Status Scale (EDSS) (FAS)

EDSS is a scale for assessing neurologic impairment in MS. It is a two-part system including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The definition of disability progression was based on increases in EDSS from baseline and depended on the EDSS baseline value: Disability progression was defined as a 1.5 increase in EDSS from baseline in subjects with a baseline EDSS score between 0.0 and 0.5, as a 1.0 increase in EDSS from baseline in subjects with a baseline EDSS score between 1.0 and 5.0 inclusive and 0.5 increase from baseline in subjects with EDSS score \> 5.0.

Time frame:
Baseline up to approximately 48 months
Reported as:
Number · percentage of participants
Percentage of Participants With Disability Progression as Measured by Expanded Disability Status Scale (EDSS) (FAS)
percentage of participantsFingolimod
Percentage of Participants With Disability Progression as Measured by Expanded Disability Status Scale (EDSS) (FAS)21.54
SecondaryChange From Baseline in Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at Month 6 and Month 48 (FAS)

EDSS is a scale for assessing neurologic impairment in MS. It is a two-part system including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The definition of disability progression was based on increases in EDSS from baseline and depended on the EDSS baseline value: Disability progression was defined as a 1.5 increase in EDSS from baseline in subjects with a baseline EDSS score between 0.0 and 0.5, as a 1.0 increase in EDSS from baseline in subjects with a baseline EDSS score between 1.0 and 5.0 inclusive and 0.5 increase from baseline in subjects with EDSS score \> 5.0.

Time frame:
Baseline, month 6 up to approximately 48 months
Reported as:
Mean · scores on a scale
Change From Baseline in Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at Month 6 and Month 48 (FAS)
scores on a scaleFingolimod
Baseline2.7 ± 1.17
Month 62.6 ± 1.38
Month 482.7 ± 1.52
Change from baseline to month 6-0.1 ± 0.69
Change from month 6 to month 480.2 ± 1.18
Change from baseline to month 480.0 ± 1.19
SecondaryChange in Immune Status of B Cells, Monocytes and Natural Killer Cells (NK) Cells (FAS)

Changes in immune status of B cells (CD19+, CD20+, CD69+), monocytes (CD14+) and NK cells (CD56+) were analyzed as a percentage of parent cell population (CD4+, CD8+ or total lymphocytes) by flow cytometry

Time frame:
Baseline up to approximately 48 months
Reported as:
Least squares mean · percentage of parent population
Change in Immune Status of B Cells, Monocytes and Natural Killer Cells (NK) Cells (FAS)
percentage of parent populationFingolimod
B cells-7.2 ± 0.42
Monocytes42.3 ± 2.03
Natural Killer cells28.0 ± 2.09

Adverse events

Collected over (Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.(approximately 48 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod 0.5 mg—0/130 (0%)1/130 (0.8%)
Most frequent other events
Most frequent other events
EventFingolimod 0.5 mg
Blood immunoglobulin M decreasedInvestigations1/130

Baseline characteristics

Age, Continuous
Age, Continuous(years)Fingolimod
Mean40.1 ± 8.54
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod
Female83
Male47
Multiple Sclerosis History at screening of CFTY720DDE01 (Core)
Multiple Sclerosis History at screening of CFTY720DDE01 (Core)(years)Fingolimod
Difference of first symptons and diagnosis2.4 ± 3.56
Difference of dagnosis and tx start in Core8.6 ± 6.23
08

Study locations

26 sites
  • Novartis Investigative Site
    Ostfildern, Baden-Wuerttemberg 73760, Germany
  • Novartis Investigative Site
    Altenholz-Stift, 24161, Germany
  • Novartis Investigative Site
    Aschaffenburg, 63739, Germany
  • Novartis Investigative Site
    Berlin, 10713, Germany
  • Novartis Investigative Site
    Berlin, 12163, Germany
  • Novartis Investigative Site
    Berlin, 13347, Germany
  • Novartis Investigative Site
    Boblingen, 71032, Germany
  • Novartis Investigative Site
    Celle, 29223, Germany
  • Novartis Investigative Site
    Dortmund, 44137, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Erbach, 64711, Germany
  • Novartis Investigative Site
    Frankfurt, 60313, Germany
  • Novartis Investigative Site
    Göttingen, 37073, Germany
  • Novartis Investigative Site
    Jena, 07740, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Klingenmünster, 76889, Germany
  • Novartis Investigative Site
    Lappersdorf, 93138, Germany
  • Novartis Investigative Site
    Leverkusen, 51375, Germany
  • Novartis Investigative Site
    Mönchengladbach, 41239, Germany
  • Novartis Investigative Site
    München, 81829, Germany
  • Novartis Investigative Site
    Neuburg an der Donau, 86633, Germany
  • Novartis Investigative Site
    Siegen, 57076, Germany
  • Novartis Investigative Site
    Singen, 78224, Germany
  • Novartis Investigative Site
    Troisdorf, 53844, Germany
  • Novartis Investigative Site
    Ulm, 89073, Germany
  • Novartis Investigative Site
    Unterhaching, 82008, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Nov 2016, 6 months.

Results were first posted in Feb 2019, 2 years 2 months after primary completion.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2016
First posted
Mar 25, 2016
StartActual
May 12, 2016
Primary completionActual
Nov 14, 2016
CompletionActual
Nov 14, 2016
Results first posted
Feb 8, 2019
Last update
Feb 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02720107
Responsible party
Sponsor
First posted
Mar 25, 2016
Start date
May 12, 2016
Primary completion
Nov 14, 2016
Completion
Nov 14, 2016
Results posted
Feb 8, 2019
Last update
Feb 8, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion